Physician profile
Julia Lake
NPI 1104203702
$3,349.33
in general payments reported to CMS, 2019-2025
31 companies · $833 in 2025
The $833 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.65 · 2021: $344 · 2022: $931 · 2023: $773 · 2024: $448 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $662.47 | 2021-2024 | Mounjaro, Lyumjev, Jardiance |
| Insulet Corporation | $554.19 | 2021-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $201.24 | 2021-2023 | |
| Lifescan, INC. | $181.23 | 2022-2023 | |
| Novo Nordisk INC | $176.43 | 2021-2023 | Rybelsus, Ozempic |
| Mannkind Corporation | $171.97 | 2020-2025 | |
| Medtronic, INC. | $166.50 | 2021-2024 | Minimed 780g |
| Dexcom, INC. | $154.59 | 2021-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $131.80 | 2022-2023 | Tymlos |
| Antares Pharma, INC. | $118.40 | 2021-2023 | Nocdurna, Xyosted, Tlando |
| Cequr Corporation | $100.16 | 2024-2025 | Cequr Simplicity |
| Beta Bionics, INC. | $99.22 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amgen INC. | $98.58 | 2021-2023 | Prolia, Evenity |
| Tandem Diabetes Care, INC. | $82.79 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $45.10 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $42.21 | 2022-2023 | Tepezza |
| Sequel Med Tech, LLC | $38.03 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $36.87 | 2022-2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $32.88 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.71 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $30.89 | 2022-2023 | Unithroid |
| Amryt Pharma Holdings LTD | $23.27 | 2022 | |
| Merck Sharp & Dohme LLC | $21.83 | 2021 | |
| Ascensia Diabetes Care US INC. | $21.24 | 2025 | |
| Recordati_rare_diseases_inc. | $19.47 | 2023 | Signifor Lar, Isturisa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.27 | 2023 | Jardiance |
| Eisai INC. | $18.85 | 2022 | |
| Abbvie INC. | $17.70 | 2023 | |
| Rgh Enterprises LLC | $17.60 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $16.99 | 2022 | |
| Halozyme INC | $15.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Lake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.